Merck & Company Inc. Common Stock (new) (MRK)
Stock · NYSE · Health Care
$145.95as of 10/16/2026
Price chart
Active signals
MRK Signal Track Record
How signals performed across all stocks →What MRK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 27 | +2.5% | 63% | September 8, 2026 |
| Bollinger Band Breakdown | 23 | +2.7% | 78% | October 5, 2026 |
| Bollinger Band Breakout | 21 | +0.9% | 62% | August 13, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +2.4% | 60% | November 3, 2025 |
| Any 20-session window (baseline) | +0.9% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. Th…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 73,000
- Website
- www.merck.com/
Fundamentals
- 1-day range
- $141.39$146.68
- Market cap
- $317.05B
- P/E (trailing)
- 112.60
- P/E (forward)
- 15.62
- EPS (trailing)
- $1.25
- Dividend yield
- 2.87%
- Beta
- 0.12
- Avg. volume
- 9.81M
- Ex-dividend date
- September 15, 2026
- Dividend pay date
- October 7, 2026
How Merck & Company Inc. Common Stock (new) Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
25 analyst ratings
Merck & Company Inc. Common Stock (new) Competitors
Chosen by industry and closest market cap.
- MRKMerck & Company Inc. Common Stock (new)$145.95▲ 0.52%Market cap $317.05BP/E 112.60$82.01$156.92
- NVSNovartis AG Common Stock$150.62▲ 0.16%Market cap $294.26BP/E 21.21$97.05$132.68
- AZNAstraZeneca PLC Ordinary Shares$165.41▼ 0.76%Market cap $249.78BP/E 24.19$11,404$15,730
- NVONovo Nordisk A/S Common Stock$38.83▼ 0.99%Market cap $203.55BP/E 9.74$224.25$409.95
- ABBVAbbVie Inc. Common Stock$285.42▲ 0.71%Market cap $430.95BP/E 79.39$190.75$285.4
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MRK Merck & Company Inc. Common Stock (new) | $317.05B | 112.60 | $145.95 | ▲ 0.52% | $82.01$156.92 |
| NVS Novartis AG Common Stock | $294.26B | 21.21 | $150.62 | ▲ 0.16% | $97.05$132.68 |
| AZN AstraZeneca PLC Ordinary Shares | $249.78B | 24.19 | $165.41 | ▼ 0.76% | $11,404$15,730 |
| NVO Novo Nordisk A/S Common Stock | $203.55B | 9.74 | $38.83 | ▼ 0.99% | $224.25$409.95 |
| ABBV AbbVie Inc. Common Stock | $430.95B | 79.39 | $285.42 | ▲ 0.71% | $190.75$285.4 |
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- A COVID Vaccine Stock on the S&P 500 Is Up 600% This YearYahoo · 10/10/2026
- Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026Yahoo · 10/10/2026
- Merck (MRK) Stock Trades Below Fair Value Despite Its 117% RunYahoo · 10/10/2026
- John Moolenaar Urges Defense Department to Add 120 Chinese Schools and Tech Labs to US Research Funding WatchlistBenzinga · 10/10/2026
- Why Is Everyone Ignoring Gilead Stock's High Cash Yield?Yahoo · 10/10/2026
- BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine PushYahoo · 10/10/2026
- Sector Update: Healthcare Stocks Gain Late AfternoonYahoo · 10/9/2026
- Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine InitiativeYahoo · 10/9/2026
Insider Activity
Insider Actions →- Seidman Christine E · September 30, 2026 · Grant56 @ $145.31
- Karsanbhai Surendralal Lanca · September 30, 2026 · Grant112 @ $145.31
- Coe Mary Ellen · September 30, 2026 · Grant206 @ $145.31
- Chirfi Guindo · August 13, 2026 · Sale10.0K @ $135
- Jennifer Zachary · August 12, 2026 · Option Exercise13.4K @ $84.71
- Jennifer Zachary · August 12, 2026 · Option Exercise41.5K @ $117.89
- Jennifer Zachary · August 12, 2026 · Sale80.3K @ $133.46
- Richard R. DeLuca · August 12, 2026 · Sale600 @ $132.04
- Richard R. DeLuca · August 12, 2026 · Sale11.1K @ $131.61
- Richard R. DeLuca · August 11, 2026 · Sale5.4K @ $132.35
- Richard R. DeLuca · August 11, 2026 · Sale7.4K @ $131.33
- Richard R. DeLuca · August 10, 2026 · Sale20.8K @ $130.43
- Chirfi Guindo · August 6, 2026 · Sale15.0K @ $131
- Richard R. DeLuca · August 6, 2026 · Sale300 @ $131.02
- Richard R. DeLuca · August 6, 2026 · Sale4.9K @ $130.23
Institutional Ownership
March 31, 2026
- Total shares held
- 1.82B
- Total value held
- $209.80B
- Institutional holders
- 3703
- Unknown225.93M
- Unknown160.99M
- Unknown119.33M
- Unknown84.31M
- Unknown59.56M
- Unknown49.77M
- Unknown47.63M
- Unknown44.52M
- Unknown30.77M
- Unknown27.09M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Merck Stock Rally Draws Attention to Valuation Concerns
Recent market commentary highlights a renewed confidence in Merck, with analysts debating whether the current rally has priced in too much optimism. While comparisons with peers like AbbVie and Bristol Myers Squibb focus on dividend yields and value, the primary discussion centers on the sustainability of Merck's recent price movement. The stock's high trailing P/E ratio of 112.6 provides context for these valuation concerns, suggesting that investors are closely monitoring if the current momentum can be sustained.
Merck Stock Rally Draws Attention to Valuation Concerns. Recent market commentary highlights a renewed confidence in Merck, with analysts debating whether the current rally has priced in too much optimism. While comparisons with peers like AbbVie and Bristol Myers Squibb focus on dividend yields and value, the primary discussion centers on the sustainability of Merck's recent price movement. The stock's high trailing P/E ratio of 112.6 provides context for these valuation concerns, suggesting that investors are closely monitoring if the current momentum can be sustained.